Axsome Therapeutics, Inc.
Informe acción DB:19X
Capitalización de mercado: €4.1b
Axsome Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 0/6 Los beneficios de Axsome Therapeutics han disminuido a una tasa media anual de -30.2%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 13.1% anualmente. Los ingresos han ido creciendo a una tasa media de 83% al año.
Información clave
-30.2%
Tasa de crecimiento de los beneficios
-23.6%
Tasa de crecimiento del BPA
Crecimiento de la industria Pharmaceuticals 7.3% Tasa de crecimiento de los ingresos 83.0% Rentabilidad financiera -300.0% Margen neto -105.9% Última actualización de beneficios 30 Jun 2024
Actualizaciones de resultados anteriores recientes
Axsome Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 15
Second quarter 2024 earnings released: US$1.67 loss per share (vs US$1.54 loss in 2Q 2023) Aug 06
Axsome Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 12
First quarter 2024 earnings released: US$1.44 loss per share (vs US$0.26 loss in 1Q 2023) May 06
Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 11
Full year 2023 earnings released: US$5.27 loss per share (vs US$4.60 loss in FY 2022) Feb 22
Mostrar todas las actualizaciones
Axsome Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 15
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine Sep 05
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc Aug 21
New minor risk - Share price stability Aug 07
Second quarter 2024 earnings released: US$1.67 loss per share (vs US$1.54 loss in 2Q 2023) Aug 06
Axsome Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 12
Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd Jun 06
Forecast breakeven date pushed back to 2026 May 07
First quarter 2024 earnings released: US$1.44 loss per share (vs US$0.26 loss in 1Q 2023) May 06
Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024 Apr 28
Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 11
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder Apr 02 Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder Mar 19
Full year 2023 earnings released: US$5.27 loss per share (vs US$4.60 loss in FY 2022) Feb 22
Forecast to breakeven in 2025 Feb 20
Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Jan 24
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers Nov 17
Forecast to breakeven in 2025 Nov 08
Third quarter 2023 earnings released: US$1.32 loss per share (vs US$1.08 loss in 3Q 2022) Nov 07
Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference Oct 25 Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors Oct 12
Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 11
Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 13
Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults Jul 08 Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million. Jun 30
Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million. Jun 29
Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023 Jun 02
Forecast to breakeven in 2025 Apr 27
Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 01
Forecast to breakeven in 2025 Dec 31
Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting Dec 08
Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation Nov 29
Insufficient new directors Nov 16
Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 22
Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults Oct 21
No longer forecast to breakeven Oct 20
Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Oct 04
Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting Sep 30
Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation Sep 09
Forecast to breakeven in 2024 Sep 08
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research Sep 08
Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor Sep 02
Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults Aug 20
No longer forecast to breakeven Aug 11
Axsome Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 29
Axsome Therapeutics, Inc. Receives from the U.S. Food and Drug Administration Jun 28
The Gross Law Firm Notifies Shareholders of Axsome Therapeutics, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 12, 2022 Jun 09
Axsome Therapeutics Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs-05 on Anhedonia in Patients with Major Depressive Disorder Jun 04
Axsome Therapeutics, Inc. Presents New Data from the Gemini Trial Demonstrating Efficacy of Axs 05 on Anhedonia in Patients with Major Depressive Disorder Jun 03 Axsome Therapeutics Announces Positive Results of the Evolve Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in the Journal of Clinical Psychiatry Jun 01
Axsome Therapeutics Announces Publication of Pivotal Ascend Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of Psychiatry May 19
Pomerantz Law Firm Announces the Filing of A Class Action Against Axsome Therapeutics, Inc. and Certain Officers May 14
No longer forecast to breakeven May 03
Insufficient new directors Apr 27 Axsome Therapeutics, Inc. to Report Q1, 2022 Results on May 02, 2022
Axsome Therapeutics, Inc., Annual General Meeting, Jun 03, 2022 Apr 23
Axsome Therapeutics, Inc. (NasdaqGM:AXSM) agreed to acquire Sunosi® from Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) for $53 million. Mar 29
Axsome Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 16
Axsome and Baudax Bio, Inc. Enters into Litigation Discontinuance Agreement Feb 08
Forecast to breakeven in 2024 Jan 01
Independent Lead Director recently bought €130k worth of stock Nov 24
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy Sep 19
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine Sep 15
Axsome Therapeutics, Inc. Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder Aug 24
No longer forecast to breakeven Aug 10
Axsome Therapeutics, Inc. Notifies the U.S. Food and Drug Administration Rescinding the Company’s Breakthrough Therapy Designation for Its AXS-12 Product Candidate for the Treatment of Cataplexy in Narcolepsy Jul 15
Axsome Therapeutics, Inc. Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia Jun 16
Axsome Therapeutics, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder Apr 27
New 90-day low: €56.14 Feb 23
Axsome Therapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Feb 17
Axsome Therapeutics, Inc Announces Results from the Company's MOVEMENT trial of AXS-07 Jan 02 Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
New 90-day high: €69.76 Dec 24
Axsome Therapeutics, Inc. Announces Positive Results from the Comet-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation Dec 10
Axsome Therapeutics, Inc. Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression Dec 03
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder Dec 02
New 90-day low: €55.69 Nov 07
Axsome Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
New 90-day low: €57.79 Oct 22
Axsome Therapeutics, Inc. announced that it expects to receive $225 million in funding from Hercules Capital, Inc., and other investors Sep 30
Axsome Therapeutics, Inc. Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Sep 26
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting Sep 22
New 90-day low - €60.36 Sep 03
Axsome Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Jul 31
New 90-day low - €62.70 Jul 30
Desglose de ingresos y gastos
Cómo gana y gasta dinero Axsome Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos DB:19X Ingresos, gastos y beneficios (USD Millions) Fecha Ingresos Beneficios Gastos G+A Gastos de I+D 30 Jun 24 291 -309 373 146 31 Mar 24 251 -296 348 117 31 Dec 23 271 -239 323 98 30 Sep 23 223 -202 297 82 30 Jun 23 182 -184 256 68 31 Mar 23 145 -159 208 63 31 Dec 22 50 -187 159 58 30 Sep 22 26 -160 117 57 30 Jun 22 9 -150 96 55 31 Mar 22 0 -141 81 54 31 Dec 21 0 -130 67 58 30 Sep 21 0 -126 58 62 30 Jun 21 0 -114 44 63 31 Mar 21 0 -100 35 59 31 Dec 20 0 -103 29 70 30 Sep 20 0 -99 24 62 30 Jun 20 0 -95 21 63 31 Mar 20 0 -90 16 63 31 Dec 19 0 -68 14 54 30 Sep 19 0 -53 11 41 30 Jun 19 0 -42 10 32 31 Mar 19 0 -37 10 26 31 Dec 18 0 -31 9 23 30 Sep 18 0 -29 9 21 30 Jun 18 0 -27 9 19 31 Mar 18 0 -26 8 19 31 Dec 17 0 -29 7 20 30 Sep 17 0 -29 7 21 30 Jun 17 0 -30 7 22 31 Mar 17 0 -29 7 22 31 Dec 16 0 -27 6 21 30 Sep 16 0 -23 5 18 30 Jun 16 0 -21 4 14 31 Mar 16 0 -16 3 10 31 Dec 15 0 -12 2 7 30 Sep 15 0 -10 2 6 30 Jun 15 0 -6 2 6 31 Mar 15 0 -6 2 5 31 Dec 14 0 -6 1 4
Ingresos de calidad: 19X actualmente no es rentable.
Margen de beneficios creciente: 19X actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 19X no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 30.2% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 19X en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: 19X no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (28.7%).
Rentabilidad financiera
Alta ROE: 19X tiene una rentabilidad financiera negativa (-300%), ya que actualmente no es rentable.
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}